前立腺癌および骨転移を有する患者の治療における、ゾレドロン酸併用または非併用の男性ホルモン遮断療法

基本情報

NCT ID: NCT00685646
ステータス: 完了
試験のフェーズ: 第3相
試験タイプ: 介入
目標被験者数: 227
治験依頼者名: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

概要

RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen blockade therapy may lessen the amount of androgens made by the body. Zoledronic acid may help relieve some of the symptoms caused by bone metastasis. It is not yet known whether androgen-blockade therapy is more effective with or without zoledronic acid in treating patients with prostate cancer that has spread to the bone. PURPOSE: This randomized phase III trial is studying androgen-blockade therapy given together with zoledronic acid to see how well it works compared with androgen-blockade therapy alone in treating patients with prostate cancer and bone metastases.

対象疾患

Metastatic CancerProstate Cancer

介入

antiandrogen therapy(DRUG)

zoledronic acid(DRUG)

依頼者（Sponsor）

Translational Research Center For Medical Innovation, Kobe, Hyogo, Japan(OTHER)

Kyoto University, Graduate School Of Medicine(OTHER)

実施施設 (1)

京都大学医学部附属病院

Kyoto, Kyoto, Japan